Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study

Journal of Pharmaceutical Analysis

Volumn 2, Issue 3, 2012, Pages 167-173

  Kumari Karra, Vijaya ^a   Rao Pilli, Nageswara ^a   Kumar Inamadugu, Jaswanth ^b   Seshagiri Rao, J V L N ^c  

^a JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^b SRI VENKATESWARA UNIVERSITY   (India)

^c ANDHRA UNIVERSITY   (India)

Author keywords

Candesartan; Human plasma; LC MS MS; Pharmacokinetics; Pioglitazone; Solid phase extraction

Indexed keywords

CANDESARTAN; IRBESARTAN; PIOGLITAZONE;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PLASMA; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

EID: 84925835423     PISSN: 20951779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpha.2012.01.002     Document Type: Article

References (17)

1. C.A. Hofmann, C.W. Edwards, and J.R. Colca Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression Endocrinology 130 1 1992 735 740
2. R.F. Kletzien, L.A. Foellmi, and P.K. Harris Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent Mol. Pharmacol. 42 4 1992 558 562
3. H.Y. Zhang, S.R. Reddy, and T.A. Kotchen Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity Hypertension 24 1994 106 110
4. J. Chilcott, P. Tappenden, and M. Lloyd A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus Clin. Ther. 23 11 2001 1792 1823
5. A.D. Dobrian, S.D. Schriver, and A.A. Khraibi Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity Hypertension 43 2004 48 56
6. C.H. Gleiter, C. Jagle, and U. Gresser Candesartan Cardiovasc. Drug Rev. 22 4 2004 263 284
7. T. Nakamura, E. Yamamoto, and K. Kataoka Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan Hypertension 51 2008 296 301
8. Y.J. Xue, K.C. Turner, and J. Pursley Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study J. Chromatogr. B 795 2003 215 226
9. M. Levi, G. Wuerzner, and E. Ezan Direct analysis of valsartan or candesartan in human plasma and urines by on-line solid phase extraction coupled to electrospray tandem mass spectrometry J. Chromatogr. B 877 2009 919 926
10. C. Hess, F. Musshoff, and B. Madea Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry Anal. Bioanal. Chem. 400 2011 33 41
11. Z.J. Lin, W. Ji, and D. Desai-Krieger Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC-/MS/MS J. Pharm. Biomed. Anal. 33 2003 101 108
12. S.T. Prajapati, P.K. Patel, and M. Patel Development and validation of the liquid chromatography-tandem mass spectrometry method for the quantitative estimation of candesartan from human plasma Pharm. Methods 2 2011 130 134
13. P. Sengupta, A.K. Sarkar, and U. Bhaumik Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application Biomed. Chromatogr. 24 2010 1342 1349
14. S.V.S.G.B. Prasad, S. Shiva Kumar, and T. Sudhir LC/MS/MS method for the simultaneous estimation of losartan potassium and irbesartan in rat plasma Int. J. Pharm. Pharm. Sci. 1 2009 206 215
15. US DHHS, FDA, CDER. Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CV), 2001. Available at: http://www/fda.gov/cder/guidance/ index.htm.
16. P. Sripalakit, P. Neamhom, and A. Saraphanchotiwitthaya High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study J. Chromatogr. B 843 2006 164 169
17. E.A. Junior, L.F. Duarte, and L. Oliveira Evaluation of the pharmacokinetic interaction between candesartan cilexetil and felodipine J. Bioequiv. Availab. 3 2011 5 10